The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
When under stress, some people grind their teeth. Though, there are several more reasons those with Hep C are vulnerable to and more prone to complications of teeth grinding.
Continue reading »Two Hepatitis C Phase 1 studies are set to evaluate the safety and tolerability of NS5B polymerase inhibitors from Vertex and Alios BioPharma.
Continue reading »A recently presented study further confirms the association between Hepatitis C infection and coronary artery disease.
Continue reading »Learn about the new research indicating that green tea could prevent the recurrence of Hepatitis C after a liver transplant.
Continue reading »After three months, a Phase 2a trial of Biotron's first-in-class direct acting Hepatitis C antiviral boasted a complete viral response for 87 percent of participants.
Continue reading »Achillion's Phase 1b Hepatitis C trial for ACH-2928, their first generation inhibitor of the NS5A protein, posted good antiviral activity, safety and tolerability results after just three days.
Continue reading »A collaboration between pharma giants Bristol-Myers Squibb and Tibotec has been established to investigate Daclatasvir plus TMC435 against Hepatitis C genotype 1.
Continue reading »OraSure's rapid Hepatitis C blood test can turn out results in just 20 minutes - a convenience that has earned it a waiver to increase its availability.
Continue reading »Because conflicting information about milk thistle can be confusing to those wanting to protect their liver, get the whole story about the latest study.
Continue reading »When it comes to slaying the "Hepatitis C dragon," two swords are better than one.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
